title: [Molecular control of bone resorption in chronic otitis media with cholesteatoma].
abstract: Bone destruction in chronic otitis media with cholesteatoma is a common phenomenon. Expanding growth of cholesteatoma in the middle ear causes ischemia of the mucosa and bones with granulation tissue production.
  
  
  OBJECTIVE
  was to assess the expression and distribution of the key regulators of bone destruction: osteoprotegerin (OPG), Receptor Activator for Nuclear Factor kappa B Ligand (RANKL) and tumour necrosis factor alpha (TNF-alpha) in chronic otitis media with cholesteatoma and their role in the pathomechanism of bone resorption.
  
  
  METHODS
  We performed immunohistochemical study of the cholesteatoma tissue collected from 21 patients suffering from chronic otitis media with cholesteatoma and 16 samples of normal external auditory meatal skin. This material was analysed histopathologically and by means of immunoperoxidase immunohistochemical technique with the use of antibodies against OPG, RANKL and TNF-alpha and their quantitive evaluation.
  
  
  RESULTS
  In all patients with cholesteatoma, features of auditory ossicles and temporal bone destruction were demonstrated. We found that cholesteatoma and granulation tissue cells release factors of the OPG/ RANKL/RANK system and TNF-alpha. In cholestatoma a higher expression of RANKL, OPG and TNF-alpha positive was demonstrated when comparing to the skin of external auditory meatus. These factors were relatively higher expressed in the stroma rather than in the epithelium of cholesteatoma. RANKL-positive cells were demonstrated mainly in the stroma cells, whereas OPG-positive ones in the cholesteatoma epithelium. The reaction with the antibodies against OPG, RANKL and TNF-alpha was weak in the external auditory meatal skin.
  
  
  CONCLUSIONS
  Bone destruction in chronic otitis media with cholesteatoma is a common process dependent on osteoclast activating factors. OPG/ RANKL/RANK system and TNF-alpha play a key role in the process of osteolysis in otitis media with cholesteatoma. We found no positive correlation between bone destruction advancement and the level of examinated proteins.
authors.affiliation: Katedra i Klinika Chorób Uszu, Nosa, Gardła i Krtani, Gdański Uniwersytet Medyczny. jerzyk@amg.gda.pl
authors.forename: Jerzy
authors.initials: J
authors.lastname: Kuczkowski
authors.forename: Grazyna
authors.initials: G
authors.lastname: Kobierska-Gulida
authors.forename: Ewa
authors.initials: E
authors.lastname: Izycka-Swieszewska
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Potocka
authors.forename: Bogusław
authors.initials: B
authors.lastname: Mikaszewski
authors.forename: Wojciech
authors.initials: W
authors.lastname: Sierszeń
mesh_terms: D000328:Adult; D000368:Aged; D001862:Bone Resorption / Q000378:metabolism*; D018424:Cholesteatoma, Middle Ear / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D053244:Osteoprotegerin / Q000378:metabolism*; D010033:Otitis Media / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D011044:Poland; D011379:Prognosis; D053245:RANK Ligand / Q000378:metabolism; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D055815:Young Adult
chemical_list: D053244:Osteoprotegerin; D053245:RANK Ligand; D014409:Tumor Necrosis Factor-alpha